About Zinc finger protein 630
Zinc finger protein 630 (ZNF630) is a protein
from Homo sapiens identified by UniProt accession
Q2M218, 657 residues long.
MolForge cross-references it against 0 known binders and
5 disease associations.
Target properties
| Protein name | Zinc finger protein 630 |
| UniProt accession | Q2M218 |
| Gene | ZNF630 |
| Organism | Homo sapiens |
| Length | 657 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (5)
Diseases linked to this target (Open Targets).
- Down syndrome · score 0.03
- Intellectual disability · score 0.01
- glioblastoma multiforme · score 0.00
- cancer · score 0.00
- pontocerebellar hypoplasia · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q2M218-F1 | alphafold | PREDICTED | 67.83 | — |
Amino-acid sequence (657 residues)
MIESQEPVTF EDVAVDFTQE EWQQLNPAQK TLHRDVMLET YNHLVSVGCS GIKPDVIFKL EHGKDPWIIE SELSRWIYPD RVKGLESSQQ IISGELLFQR EILERAPKDN SLYSVLKIWH IDNQMDRYQG NQDRVLRQVT VISRETLTDE MGSKYSAFGK MFNRCTDLAP LSQKFHKFDS CENSLKSNSD LLNYNRSYAR KNPTKRFRCG RPPKYNASCS VPEKEGFIHT GMEPYGDSQC EKVLSHKQAH VQYKKFQARE KPNVCSMCGK AFIKKSQLII HQRIHTGEKP YVCGDCRKAF SEKSHLIVHQ RIHTGEKPYE CTKYGRAFSR KSPFTVHQRV HTGEKPYECF ECPKAFSQKS HLIIHQRVHT REKPFECSEC RKAFCEMSHL FIHQITHTGK KPYECTECGK TFPRKTQLII HQRTHTGEKP YKCGECGKTF CQQSHLIGHQ RIHTGEKPYV CTDCGKAFSQ KSHLTGHQRL HTGEKPYMCT ECGKSFSQKS PLIIHQRIHT GEKPYQCGEC GKTFSQKSLL IIHLRVHTGE KPYECTECGR AFSLKSHLIL HQRGHTGEKP YECSECGKAF CGKSPLIIHQ KTHPREKTPE CAESGMTFFW KSQMITYQRR HTGEKPSRCS DCGKAFCQHV YFTGHQNPYR KDTLYIC
Explore Zinc finger protein 630 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets